ClinicalTrials.gg
CompletedNCT07782554Updated Aug 24, 2026

EUS-Guided Portal Pressure Gradient Measurement in Prehepatic Portal Hypertension

An observational study in Prehepatic Portal Hypertension, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
59
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 106 studies in Hypertension, Portal with a site in China — 38 open to participants now, 40 under way, none of them phase 3. Hypertension, Portal · China.

Enrollment
39th of 42
59 · median 258
Started
2025
with 9 others
Observational
42 of 106
18 open now
Registered
104th of 106
by date

Among the 106 studies in Hypertension, Portal with a site in China, this one is the 39th largest by enrollment of the 42 observational ones that give a count, is one of 10 that started in 2025, is one of 42 observational ones, and was the 104th registered.

Hypertension, Portal

376 studies on the registry are indexed under Hypertension, Portal; 115 are open to participants now.

Browse Hypertension, Portal studies →

Open to participants now

38 of the 106 studies in Hypertension, Portal with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Hypertension, Portal studies recruiting now, 33 (48%) set no upper age limit and 13 (19%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Hypertension, Portal with a site in China, or all of them as a file.
02

Study summary

Portal hypertension caused by prehepatic vascular obstruction, such as portal vein thrombosis or portal vein tumor thrombosis, represents a unique hemodynamic condition in which conventional hepatic venous pressure gradient (HVPG) measurement may not accurately reflect portal venous pressure. Endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement provides a direct approach for assessing portal hemodynamics.

This retrospective observational study included patients with cirrhosis and esophagogastric varices complicated by portal vein thrombosis or portal vein tumor thrombosis. All patients underwent abdominal computed tomography to confirm the presence of portal vein obstruction, liver stiffness measurement by ultrasound elastography, HVPG measurement, and EUS-PPG measurement. The study aims to evaluate the relationship between EUS-PPG and HVPG and to explore the associations between portal pressure measurements and clinical characteristics, including underlying liver disease etiology, liver function grade, sex, gastrointestinal bleeding, and hepatic encephalopathy.

03

Conditions studied

  • Prehepatic Portal Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study included patients with liver cirrhosis complicated by prehepatic portal hypertension due to portal venous obstruction. All patients had esophagogastric varices and underwent abdominal computed tomography, ultrasound elastography, hepatic venous pressure gradient measurement, and endoscopic ultrasound-guided portal pressure gradient measurement. The study evaluated the relationship between portal pressure measurements and clinical characteristics, including liver disease etiology, liver function grade, gastrointestinal bleeding, and hepatic encephalopathy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥18 years; Confirmed diagnosis of cirrhosis complicated by portal venous obstructionbased on clinical, laboratory, and imaging findings; Written ;

Exclusion criteria

Exclusion Criteria:

Severe coagulopathy, defined as an (INR) >1.5; Severe thrombocytopenia, defined as a count \<30 × 10\^9/L; Severe systemic comorbidities, including active sepsis, decompensated heart failure, or severe ; Psychiatric or cognitive disorders that preclude cooperation with study procedures; Refusal to undergo hepatic venous pressure gradient (HVPG) or endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement;

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
59 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Correlation Between EUS-Guided Portal Pressure Gradient and Hepatic Venous Pressure Gradient

    The correlation between portal pressure gradient measured by endoscopic ultrasound-guided direct portal pressure measurement (EUS-PPG) and hepatic venous pressure gradient (HVPG) will be assessed using paired measurements obtained during the same procedural session. Both EUS-PPG and HVPG are measured in mmHg. The strength of the correlation will be quantified using a correlation coefficient.

    Time frame: Periprocedural

Secondary outcomes

  1. Difference Between Distal-to-Obstruction and Proximal-to-Obstruction EUS-Guided Portal Pressure Gradients

    The difference between distal-to-obstruction portal pressure gradient (dis-Obs PPG) and proximal-to-obstruction portal pressure gradient (pro-Obs PPG), measured by endoscopic ultrasound-guided direct portal pressure measurement, will be assessed using paired measurements obtained during the same procedural session. Both pressure gradients are measured in mmHg.

    Time frame: Periprocedural

  2. Difference Between Distal-to-Obstruction EUS-Guided Portal Pressure Gradient and Hepatic Venous Pressure Gradient

    The difference between distal-to-obstruction portal pressure gradient (dis-Obs PPG), measured by endoscopic ultrasound-guided direct portal pressure measurement, and hepatic venous pressure gradient (HVPG), measured by standard hepatic venous catheterization, will be assessed using paired measurements obtained during the same procedural session. Both pressure gradients are measured in mmHg.

    Time frame: Periprocedural

  3. Difference in Distal-to-Obstruction EUS-Guided Portal Pressure Gradient Between Patients With and Without Variceal Bleeding

    Distal-to-obstruction portal pressure gradient (dis-Obs PPG), measured by endoscopic ultrasound-guided direct portal pressure measurement and expressed in mmHg, will be compared between patients with and without variceal bleeding related to portal hypertension.

    Time frame: Baseline

07

Study locations

1 site
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Jun 2026, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Aug 24, 2026
StartActual
Mar 1, 2025
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782554
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Mar 1, 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Aug 24, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion